NUP98–HOXA9 bearing therapy‐related myeloid neoplasm involves myeloid‐committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression. (29th September 2015)
- Record Type:
- Journal Article
- Title:
- NUP98–HOXA9 bearing therapy‐related myeloid neoplasm involves myeloid‐committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression. (29th September 2015)
- Main Title:
- NUP98–HOXA9 bearing therapy‐related myeloid neoplasm involves myeloid‐committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression
- Authors:
- Burillo‐Sanz, S.
Morales‐Camacho, R. M.
Caballero‐Velázquez, T.
Vargas, M. T.
García‐Lozano, J. R.
Falantes, J. F.
Prats‐Martín, C.
Bernal, R.
Pérez‐Simón, J. A. - Abstract:
- Summary: Introduction: Chromosomal rearrangements involving NUP98 gene have been associated with human leukemias such as de novo AML, therapy‐related AML (t‐AML), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). Genetic fusion NUP98–HOXA9, caused by t(7;11)(p15;p15), is a recurrent cytogenetic alteration in de novo acute myeloid leukemia (AML) usually found in young Asian patients and its description in therapy‐related myeloid neoplasms (t‐MN) is rare. Only one Asian case with molecular demonstration of the NUP98–HOXA9 fusion has been reported in therapy‐related leukemia. NUP98–HOXA9 leukemogenic mechanism is derived from the transcription factor activity of the chimeric protein, which enhances the expression of genes related to cellular differentiation arrest and proliferation. Patients and Methods: We studied a Caucasian woman with a therapy‐related acute myeloid leukemia after Ewing′s sarcoma. Molecular demonstration of the genetic fusion NUP98–HOXA9 was performed by RT‐PCR, and gene expression was analyzed by real‐time PCR, including four AML patients with MLL rearrangements for comparative analysis. Cytologic and flow cytometric analysis was also carried out. Results: After cytologic and flow cytometric analysis diagnostics was therapy‐related myeloid neoplasm (t‐MN). The major component of blasts in the acute leukemia was with neutrophilic differentiation, but 13% erythroid lineage blasts were also found. Cytogenetic and FISH analysis revealedSummary: Introduction: Chromosomal rearrangements involving NUP98 gene have been associated with human leukemias such as de novo AML, therapy‐related AML (t‐AML), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). Genetic fusion NUP98–HOXA9, caused by t(7;11)(p15;p15), is a recurrent cytogenetic alteration in de novo acute myeloid leukemia (AML) usually found in young Asian patients and its description in therapy‐related myeloid neoplasms (t‐MN) is rare. Only one Asian case with molecular demonstration of the NUP98–HOXA9 fusion has been reported in therapy‐related leukemia. NUP98–HOXA9 leukemogenic mechanism is derived from the transcription factor activity of the chimeric protein, which enhances the expression of genes related to cellular differentiation arrest and proliferation. Patients and Methods: We studied a Caucasian woman with a therapy‐related acute myeloid leukemia after Ewing′s sarcoma. Molecular demonstration of the genetic fusion NUP98–HOXA9 was performed by RT‐PCR, and gene expression was analyzed by real‐time PCR, including four AML patients with MLL rearrangements for comparative analysis. Cytologic and flow cytometric analysis was also carried out. Results: After cytologic and flow cytometric analysis diagnostics was therapy‐related myeloid neoplasm (t‐MN). The major component of blasts in the acute leukemia was with neutrophilic differentiation, but 13% erythroid lineage blasts were also found. Cytogenetic and FISH analysis revealed t(7;11)(p15;p15) and NUP98–HOXA9 fusion gene was demonstrated. Gene expression analysis showed upregulation of EVI1 and MEIS1 in the index patient, both of them previously related to a worst outcome. Conclusion: In this work, we include a detailed molecular, clinical, cytological, and cytometric study of the second t‐AML bearing NUP98–HOXA9 genetic fusion. … (more)
- Is Part Of:
- International journal of laboratory hematology. Volume 38:Number 1(2016:Feb.)
- Journal:
- International journal of laboratory hematology
- Issue:
- Volume 38:Number 1(2016:Feb.)
- Issue Display:
- Volume 38, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 38
- Issue:
- 1
- Issue Sort Value:
- 2016-0038-0001-0000
- Page Start:
- 64
- Page End:
- 71
- Publication Date:
- 2015-09-29
- Subjects:
- NUP98 -- therapy‐related AML -- gene expression profiling
Hematology -- Periodicals
Blood -- Diseases -- Periodicals
Hematology -- Periodicals
616.15005 - Journal URLs:
- http://firstsearch.oclc.org/FSIP?db=ECO&journal=1751-5521&screen=info&done=referer ↗
http://www.blackwell-synergy.com/loi/clh ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1751-553X ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/ijlh.12435 ↗
- Languages:
- English
- ISSNs:
- 1751-5521
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.312220
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 378.xml